Felipe Cortés

MD💉🇭🇳Ginecólogo y Obstetra🤰🏼 Residente de Ginecología Oncológica🦀 📍🇲🇽

[Felipe Cortés @FelipeCortesVga]

Oficialmente primer Día como Residente de Ginecología Oncológica.

[Karamvir Yadav @K_Yadavir]

📢 New ASCO Breast Cancer Surveillance Guideline

Not every breast cancer survivor needs the same intensity of follow-up.

Risk-stratify. De-escalate when appropriate. Intensify when risk is high.

❌ Routine tumor markers
❌ Routine metastatic imaging
❌ Routine ctDNA

✅ Appropriate mammography
✅ Selective MRI
✅ Shared decision-making

Less can be more—when evidence and risk support it.

#BreastCancer #ASCO #Oncology #Survivorship @drsarahsam @DFCI_BreastOnc @OncoDailyBreast

[IJGC @IJGConline]

LNG-IUD as an alternative to hysterectomy for women with atypical endometrial hyperplasia and low-grade #endometrial cancer

✅ High success in AEH
⚠️ Caution for endometrial cancer

💡 https://t.co/eHeqTypGnZ

@pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde

[IJGC @IJGConline]

Impact of NACT on HRD test results in patients with advanced high-grade serous #ovariancancer

🧬 https://t.co/4pr3kIfvLD

@pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde

[Annals of Surgical Oncology @AnnSurgOncol]

#AudioVisualAbstract : Trends in Patient-Reported Outcomes After #BreastConservingSurgery and Partial-Breast Versus Whole- #BreastIrradiation @juliamchandler @AudreeTadros

https://t.co/XBUL3Ir1xH

@drsergioaguilar
@SyedAAhmad5

[IJGC @IJGConline]

📢 Can #SABR improve outcomes in #oligometastatic gynecologic cancers?
A narrative review of 17 studies (n=990) found:
🎯 >80% 1-year local control in several studies
⏳ Median PFS: 7.8–32 months
🛡️ Generally low severe toxicity

🔗 https://t.co/rp7LaCWs3q

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde

#IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

[IJGC @IJGConline]

#2026SpecialIssue Challenging the standard in early-stage #ovariancancer: current evidence and a standardized framework for sentinel node mapping

🔍 https://t.co/i3sb25JOWP

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @luribero26 @beatesarta @AlwynDO @PeppeParisi_ @ilkerselcukmd @VinTarantino @NSeminario27498 @dranushak88

[IJGC @IJGConline]

De-escalation in Stage IC epithelial ovarian cancer—can we safely do less? 🤔
🔬 Histology-driven decisions
🟢 Safe omission possible in select subtypes
⚖️ Balance survival benefit vs toxicity
🤝 Shared decision-making is essential

Not all Stage IC needs chemo — precision matters.

🔗 https://t.co/lawQryhd0g

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @luribero26 @beatesarta @AlwynDO @PeppeParisi_ @ilkerselcukmd @VinTarantino @NSeminario27498 @dranushak88

#IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

[IJGC @IJGConline]

Minimally invasive surgery in advanced ovarian cancer—are we ready to shift paradigms?

🔹 ↓ blood loss & complications
🔹 Faster recovery
🔹 Careful patient selection is key
🔹 Tech + AI shaping the future
📊 Evidence evolving - RCTs awaited

🔗 https://t.co/f5ttd42AcA

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @luribero26 @beatesarta @AlwynDO @PeppeParisi_ @ilkerselcukmd @VinTarantino @NSeminario27498 @dranushak88

#IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

[Dr Rishabh Jain @DrRishabhOnco]

T-DXd combinations may expand the playbook in HER2-low metastatic breast cancer.

DESTINY-Breast08, a phase Ib study, tested trastuzumab deruxtecan (T-DXd) with multiple partners in HER2-low mBC and showed encouraging early activity across several combinations.

🧪 Trial arms
• T-DXd + capecitabine
• T-DXd + capivasertib
• T-DXd + anastrozole
• T-DXd + fulvestrant

📊 Key efficacy signals
• T-DXd + capecitabine: ORR 60%
• T-DXd + capivasertib: ORR 60%
• T-DXd + anastrozole: ORR 71.4%
• T-DXd + fulvestrant: ORR 40%

⏳ Median PFS
• Capecitabine: 13.4 mo
• Capivasertib: 9.0 mo
• Anastrozole: 13.4 mo
• Fulvestrant: not reached at data cutoff

⚠️ Safety still matters
Grade 3+ AEs were common across cohorts, and adjudicated ILD/pneumonitis occurred in multiple arms, including a fatal event in the capecitabine cohort.

💡 Takeaway
This is not practice-changing yet, but it suggests that rational T-DXd combinations, especially with endocrine therapy or AKT inhibition, could be a major next step in HER2-low disease. Randomized validation is needed.

🔖 HER2-low is no longer a single-lane space.

📖 Full paper in comment ⬇️

#BreastCancer #HER2Low #TDXd #OncoTwitter #MedTwitter @OncoAlert @myesmo @esmo_open @asco @stolaney1 @PTarantinoMD

[IJGC @IJGConline]

⚖️ De-escalation in definitive #cervical cancer surgery aims to preserve survival while reducing morbidity.
✨ Simple hysterectomy in selected tumors
🧭 Sentinel node mapping
🔬 Intra-operative tailoring
🎯 Pre-operative brachytherapy

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @luribero26 @beatesarta @AlwynDO @PeppeParisi_ @ilkerselcukmd @VinTarantino @NSeminario27498 @dranushak88

🔗 https://t.co/j8e6ZS6CSC

#IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

[Dr Luis Felipe Cabrera Vargas MD FACS @PipeCabreraV]

The 6 stages of resection for retroperitoneal sarcomas 🔪⤵️💥! @SWexner @pferrada1 @BJSAcademy @BjsOpen @TomVargheseJr @juliomayol

[Dr. Mateo Avila @drteoa]

Puntos clave – Cáncer de ovario (Nature Reviews Disease Primers 2026)

1.El cáncer epitelial de ovario no es una sola enfermedad.
Incluye subtipos con biología, origen, pronóstico y tratamiento distintos.
2.El HGSOC suele originarse en la trompa de Falopio, no en el ovario.
Hoy se reconoce el extremo fimbrial como origen frecuente, con diseminación peritoneal temprana.
3.El gran problema sigue siendo el diagnóstico tardío.
La mayoría debuta en fases avanzadas, lo que explica gran parte de su mortalidad.
https://t.co/9Psuup0lHH hay un screening eficaz para población general.
Ni CA125 ni ecografía transvaginal han demostrado beneficio en mortalidad en los grandes ensayos.
5.BRCA1/2 y HRD cambiaron el enfoque clínico.
No solo aumentan el riesgo: también predicen sensibilidad a platinos y a inhibidores PARP.
6.TP53 está alterado en casi todos los HGSOC.
Es un evento molecular precoz y central en la oncogénesis de este subtipo.
7.El estándar sigue siendo cirugía + carboplatino/paclitaxel.
La meta quirúrgica ideal continúa siendo citorreducción completa a enfermedad macroscópica cero.
https://t.co/UJtePhjMQK neoadyuvancia no reemplaza a la buena cirugía primaria, pero sí tiene un lugar.
Se prefiere cuando R0 no es factible o la paciente no toleraría una cirugía agresiva inicial.
9.Los PARP inhibitors marcaron un antes y un después en mantenimiento.
El beneficio es más claro en tumores con BRCA mutado o firma HRD.
https://t.co/IixuImf3UB todos los subtipos se comportan igual.
LGSOC se relaciona con vía MAPK; clear cell y endometrioide con endometriosis; el mucinoso obliga a descartar origen GI/apendicular.
11.Bevacizumab sigue teniendo espacio en enfermedad avanzada seleccionada.
Especialmente en pacientes con ascitis, enfermedad bulky o compromiso parenquimatoso.
https://t.co/ZfzoW4u9HI biología molecular ya no es “extra”, es parte del tratamiento.
Hoy entender BRCA, HRD y subtipo histológico cambia decisiones reales.

[IJGC @IJGConline]

📊 #Radiotherapy in locally advanced #cervical cancer: a century of refinement

From radium therapy ➡️ CT-based planning ➡️ #IGRT & image-guided #brachytherapy, progress has focused on optimizing delivery, not de-escalating treatment.

Read the historic perspective @ https://t.co/g5iMMXmbFR

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @luribero26 @beatesarta @AlwynDO @PeppeParisi_ @ilkerselcukmd @VinTarantino @NSeminario27498 @dranushak88

#IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

[IJGC @IJGConline]

#2026SpecialIssue De-escalation in gynaecological oncology: when less is enough. 🎯💜

The issue is free to read all month for the global #GynOnc community.

Stay tuned… will be available on March 2nd😎

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @luribero26 @beatesarta @AlwynDO @PeppeParisi_ @ilkerselcukmd @VinTarantino @NSeminario27498 @dranushak88

[OBSTETRICS & GYNECOLOGY CONNECT powered by COR2ED @OBGynConnect]

Understanding HER2 testing in gynecological cancers: Best practices and treatment implications

✔️ Get a guideline-driven overview of immunohistochemistry testing in endometrial, cervical & ovarian cancers

✔️ Find out why accurate assessment is now critical for treatment selection

📺 From Prof. Fernando Soares

Get the slides for more details: https://t.co/irOwaUTuwZ

Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.

#MedEd #obgyn #MedTwitter

[MV Chandrakanth @ChandrakanthMv]

🧠 Cancer during pregnancy ≠ no treatment
• What imaging is safe?
• When is chemo allowed?
• Which drugs are a strict NO?
• How to plan delivery?
ASCO 2025/26 guidance—simplified for clinic. 👇
#Oncology #Pregnancy #ASCO #MedTwitter #MVOnco

[Zedu Ultrasound Training @zedunow]

How to improve the efficiency and the safety of real-time #ultrasound-guided central venous catheterization in 2023: a narrative review
via @of_aic

https://t.co/Ybme93JEoh
#POCUS #USGIV #FOAMed #meded

[Asociación ASACO @asociacionASACO]

FOLLETOS ENGAGe (Plataforma de Pacientes de @ESGO_society)

A continuación podéis ver los folletos creados por #ENGAGe. La traducción del inglés ha sido realizada por voluntarias de #ASACO.

➡️ https://t.co/AoSfA3M7Bt #cancerpatient #cancercare

[ECMO Heart Team Mx @DrECMO]

Claramente la colocación del introductor tiene varios detalles de importancia, uno de ellos es JAMÁS perder de vista la guía.
Aquí se introduce un catéter

[ECMO Heart Team Mx @DrECMO]

How to…
….teach a new skill in a low resources hospital in a 3rd world country…